ArticleBMC cancer2025
Comprehensive analysis illustrating the role of HOXB8 in head and neck squamous cell carcinoma: evidence from multi-omics analysis and experiments validation.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHOXB8 is implicated in various cancers. However, the effect pattern of HOXB8 in head and neck squamous cell carcinoma (HNSCC) remains unclear.
methodsOpen-access transcriptional profiles, clinical information, and mutational data were downloaded from the Cancer Genome Atlas database. R software was used for all analysis based on public data through specific R packages. Western blot and real-time quantitative PCR was used to detect the protein and RNA level of HOXB8, respectively. In vivo and in vitro experiments were conducted to explore the effect of HOXB8 on HNSCC cells.
resultsHere, we discovered that HOXB8 was upregulated in HNSCC tissue and associated with worse clinical outcomes (clinical stage and prognosis). Results indicated that HOXB8 was primarily distributed in the nucleoplasm. Results of cell lines indicated that HOXB8 is upregulated in HNSCC cells. Further experiments, both in vitro and in vivo, revealed that the suppression of HOXB8 can markedly curb the proliferation, invasion, and migration capabilities of HNSCC cells. Results of biological enrichment and western blot indicated that HOXB8 can regulate the PI3K/AKT/mTOR and EMT pathways. It also came to our attention that HOXB8 could modulate the tumor microenvironment in HNSCC. We observed that patients with high HOXB8 expression had lower infiltration levels of CD8 + T cells but higher infiltration levels of M2 macrophages. Finally, we developed a prognostic model based on molecules derived from HOXB8 (ADD2, SYT1, PXYLP1, MRPL33).
conclusionsOur study contributes to the existing knowledge on HOXB8 in HNSCC, which may inform future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.